Columbia Labs' Replens
This article was originally published in The Tan Sheet
Executive Summary
Columbia regains rights to the vaginal moisturizer after severing existing licensing and supply agreement with Warner-Lambert, the firm announces March 25. "Replens will fit nicely into the company's existing group of over-the-counter pharmaceutical products, which include Legatrin PM, Diasorb and Vaporizer in a Bottle," thereby "minimally affecting existing sales and marketing overhead," Columbia says. The transaction is expected to be accretive to earnings. As part of the deal, Columbia issued a $10 mil. note to a private institutional investor that is convertible into approximately 629,000 common shares and matures in seven years...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning